A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Quadrivalent human papilomavirus recombinant vaccine Shanghai Bovax Biotechnology (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Shanghai Bovax Biotechnology
- 12 Sep 2018 Status changed from active, no longer recruiting to completed.
- 30 Mar 2017 New trial record